Drug-Induced Arrhythmias, Precision Medicine, and Small Data
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
- basic science research
- ion channels/membrane transport
- precision medicine
Precision medicine refers to new treatment and prevention strategies that take individual variability into account.1 Toward that end, the National Institutes of Health Precision Medicine Initiative envisions supporting a research program to encourage creative approaches to precision medicine, test them rigorously, and ultimately use them to build the evidence base needed to guide clinical practice.2 A major component of the Precision Medicine Initiative is the National Institutes of Health All of Us Research Program, which will engage ≥1 million volunteers living in the United States to contribute their health data over many years to improve health outcomes, fuel the development of new treatments for disease, and catalyze a new era of evidence based and more precise preventive care and medical treatment.3
See Article by Yang et al
The variable clinical response to drug therapy provides an especially compelling case for the promise of the precision medicine paradigm. A significant proportion of individuals treated with drugs display either little benefit, or even more problematic, develop serious and sometimes life-threatening adverse effects. Indeed, in 2014, as many as 253 017 serious outcomes, including 123 927 deaths, were reported through the Federal Drug Administration Adverse Events Reporting System.4 Among the more devastating adverse drug effects, seen with both antiarrhythmic and noncardiac drugs, are proarrhythmia and sudden cardiac death. The recognition of this problem has …